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Summary Niraparib is an investigational oral, once daily,
selective poly(ADP-Ribose) polymerase (PARP)-1 and
PARP-2 inhibitor. In the pivotal Phase 3 NOVA/ENGOT/
OV16 study, niraparib met its primary endpoint of improving
progression-free survival (PFS) for adult patients with recur-
rent, platinum sensitive, ovarian, fallopian tube, or primary
peritoneal cancer in complete or partial response to
platinum-based chemotherapy. Significant improvements in
PFS were seen in all patient cohorts regardless of biomarker
status. This study evaluates the absorption, metabolism and
excretion (AME) of 14C–niraparib, administered to six pa-
tients as a single oral dose of 300 mg with a radioactivity of
100 μCi. Total radioactivity (TRA) in whole blood, plasma,
urine and faeces was measured using liquid scintillation
counting (LSC) to obtain the mass balance of niraparib.
Moreover, metabolite profiling was performed on selected
plasma, urine and faeces samples using liquid chromatogra-
phy – tandemmass spectrometry (LC-MS/MS) coupled to off-
line LSC. Mean TRA recovered over 504 h was 47.5% in
urine and 38.8% in faeces, indicating that both renal and
hepatic pathways are comparably involved in excretion of
niraparib and its metabolites. The elimination of 14C–radioac-
tivity was slow, with t1/2 in plasma on average 92.5 h. Oral
absorption of 14C–niraparib was rapid, with niraparib concen-
trations peaking at 2.49 h, and reaching a mean maximum
concentration of 540 ng/mL. Two major metabolites were
found: the known metabolite M1 (amide hydrolysed
niraparib) and the glucuronide of M1. Based on this study it
was shown that niraparib undergoes hydrolytic, and
conjugative metabolic conversions, with the oxidative path-
way being minimal.
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Introduction
Niraparib (MK-4827) is a novel, investigational poly(ADP-
Ribose) polymerase (PARP) inhibitor with antitumour effect
in BRCA1 and BRCA2 mutated cancer cells [1, 2]. Niraparib
has shown promising results as a monotherapy in treatment of
ovarian cancer [3] and is currently under investigation as
monotherapy against other solid tumours as well as in combi-
nation with bevacizumab and pembrolizumab [4, 5]. A dose-
escalation study revealed that a daily dose of 300 mg is well
tolerated, has favourable pharmacological properties and
antitumour activity in a broad patient population regardless
of biomarker status including BRCA1 and BRCA2 mutations
[2].
Both the US Food and Drug Administration (FDA) and the
European Medicines Agency (EMA) have emphasised the
importance of human absorption, metabolism and excretion
(AME) studies in drug discovery and drug development, and
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it is now required for regulatory filing [6, 7]. The use of
radiolabelledmolecules is a commonmethod used to ascertain
information on the excretory routes and metabolic fate of a
compound at an early stage of development [8].
Preclinical studies investigating the metabolism and dispo-
sition of niraparib in toxicological model species have shown
the formation of 22 metabolites (M1 – M22) in liver micro-
somes and hepatocyte suspensions from humans, rats and
dogs [9, 10]. This article now describes the evaluation of the
mass balance of niraparib in humans, via measurement of the
total radioactivity (TRA) of urine and faeces samples by liquid
scintillation counting (LSC), and aims to identify the major
routes of excretion as well as the metabolites formed in human
plasma, urine and faeces. Moreover, this study determines the
plasma concentration-time profiles of niraparib and its metab-




Six evaluable patients were enrolled in this open-label mass
balance clinical study (ClinicalTrials.gov identifier
NCT02476552) and were admitted to the study center for at
least 10 days, with the 11th day being optional. On Day 1,
after an overnight fast, patients received an oral dose
consisting of three capsules of 100 mg radiolabelled
niraparib (Quotient Clinical, Ruddington, Nottingham, UK)
with a total radioactivity of 100 μCi. From the moment of
administration, all urine and faeces were collected.
Following completion of the study, subjects were considered
eligible for continued treatment with niraparib through
participation in the extension study, which involved the daily
intake of 300 mg unlabelled niraparib (1 cycle =28 days). The
objective of this part of the study was to evaluate the safety
and tolerability of niraparib in subjects with cancer. Dose
reductions were allowed twice. The study was conducted in
conformance with the International Conference on
Harmonisation (ICH) guidelines for Good Clinical Practice
(GCP) and in accordance with the Declaration of Helsinki.
The protocol was approved by the Netherlands Cancer
Institute Independent Ethics Committee. All patients provided
written informed consent.
Patients
Patients aged ≥18 years with a histologically or cytologically
confirmed diagnosis of metastatic or locally advanced solid
tumours who had failed to respond to standard therapy, had
progressed despite standard therapy, or for whom no standard
therapy existed, and might benefit from treatment with a
PARP inhibitor were eligible for this study. Other inclusion
criteria included adequate organ function, such as bone mar-
row function (absolute neutrophil count ≥1500/μL, platelets
≥100,000/μL, and haemoglobin ≥9 g/dL); adequate renal
function (serum creatinine ≤1.5 x upper limit of normal
(ULN) or a calculated creatinine clearance ≥60 mL/min);
and adequate hepatic function (total bilirubin ≤1.5 x ULN or
direct bilirubin ≤1 x ULN, alanine aminotransferase (ALAT)
and aspartate aminotransferase (ASAT) ≤2.5 x ULN, or ≤5 in
case of liver metastases). An Eastern Cooperative Oncology
Group (ECOG) performance status of 0–2 was required and
adequate use of birth control was mandatory for the duration
of the study. Patients were excluded from the study if they had
undergone palliative radiotherapy within a week of niraparib
administration; had >grade 2 toxicity from prior cancer thera-
py; had symptomatic uncontrolled brain or leptomeningeal
metastases; had known hypersensitivity to the components
of niraparib; had major surgery within 3 weeks of niraparib
administration; were considered a medical risk due to a seri-
ous, uncontrolled medical disorder; or had received a platelet
transfusion within 4 weeks of niraparib administration.
Immunocompromised patients as well as patients with con-
firmed or expected hepatitis B virus (HBV), hepatitis C
(HCV), or human immunodeficiency virus (HIV) were also
excluded from the study. Moreover, patients were refrained
from taking QTc prolonging medication, proton pump inhib-
itors, and H2 blockers. Pregnant women were also excluded
from the study.
Study medication
Radiolabelled niraparib was manufactured, packed and la-
belled by Quotient Clinical (Ruddington, Nottingham, UK).
14C–Niraparib capsules for oral administration were transpar-
ent hard gelatine capsules containing 100 mg niraparib (hot
and cold) free base as the tosylate monohydrate salt (Fig. 1).
Each capsule did not contain more than 1.23MBq (33.33μCi)
14C–niraparib drug substance. The oral formulation was pre-
pared by radiodiluting a 14C–precursor compound to produce
14C–niraparib, which was subsequently combined with
niraparib cold component at a ratio of 570:1 to obtain a spe-

















Fig. 1 Molecular structure of 14C-niraparib tosylate
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substance were then added to capsules, to obtain capsules
containing 100mg (33.33μCi) niraparib. The final dose given
to each patient was 300 mg (100 μCi). The chemical purity
and radiochemical purity of each manufactured batch was
≥98%. Each bottle contained a single dose of 3 x 14C–niraparib
capsules and each patient enrolled in the clinical trial was
assigned one bottle. Nonlabelled niraparib was manufactured
by Merck Sharpe & Dohme Corp. (Rayway, NJ, USA). Once
enrolled in the extension part, patients received a bottle con-
taining 93 capsules of unlabelled niraparib. These bottles were
packed and labelled by Almac (Craigavon, UK).
Chemicals
Acetonitrile, methanol and water (all Supra-Gradient grade)
were suppl ied by Biosolve Ltd. (Valkenswaard,
The Netherlands). Formic acid (≥98%; analytical grade), 2-
propanol (>99.8%), hydrogen peroxide (30%), ethylenedi-
aminetetraacetic acid (EDTA) 99% and sodium hydroxide
(50%) were provided by Merck (Amsterdam, the
Netherlands). Ammonium acetate (LC-MS grade) was pur-
chased from Sigma Aldrich (Zwijndrecht, the Netherlands).
Ultima Gold™ and Solvable™ were obtained from
PerkinElmer (Groningen, the Netherlands). Water was pur-
chased from B. Braun (Oss, the Netherlands).
Sample collection
Blood sampling was done at the following time points: pre-
dose, 1, 1.5, 2, 3, 4, 6, 9 and 12 hours (h) after administration
and in the morning of Day 2, 3, 4, 5, 8, 11, 15 and 22. For each
time point, a 10 mL K2EDTA blood collection tube was used
(Vacutainer®, Becton, Dickinson and Company, Franklin
Lakes, NJ, USA) and blood was drawn via a peripheral line.
Whole blood aliquots were taken for radioactivity measure-
ments, after which the tube was centrifuged (3000 rpm,
10 min, 4 °C) to produce plasma. Separate aliquots were made
for radioactivity measurements as well as LC-MS/MS and
metabolite profiling experiments. All samples were stored at
−80 °C.
For the purpose of the mass balance study and metabolite
profiling, urine and faecal samples were collected. Urine was
collected at pre-determined intervals: pre-dose, 0–12 h, 12–
24 h, 24–36 h and 36–48 h after administration. From Day 3
onwards, urine was collected over periods of 24 h. Urine was
stored in polyethylene containers at 2–8 °C for the duration of
the collection period. After each collection period, urine sam-
ples were mixed thoroughly, weighed, portioned into aliquots,
and then frozen at ≤ − 70 °C. Separate aliquots were made in
polypropylene tubes for analysis by LC-MS/MS, metabolite
profiling and TRA analysis by LSC.
Faeces were collected and weighted per stool. Sample pre-
treatment involved diluting and homogenising the faeces by
adding water (1:3 w/v; B. Braun). A T25 basic Ultra Turrax
(IKAWorks, Staufen, Germany) was used to homogenise the
samples before aliquoting. Urine and faeces sample collection
occurred according to the following requirements:
1. If the total radioactivity in the Day 14 faecal/urine sample
is detected to be higher than 0.1% and the total recovery
of accumulative radioactivity ≤85% (faeces and urine) of
the radioactivity of the dose given, faecal/urine samples
will be collected every 24 h through Day 21.
2. If the total radioactivity in the Day 21 faecal/urine sample
is detected to be higher than 0.1% and the total recovery
of accumulative radioactivity ≤85% (faeces and urine),
faecal/urine samples will continue to be collected every
24 h.
3. Faecal/urine sample collection will stop after Day 21, if
the recovered radioactivity is below 1% (per 24 h) for the
two consecutive days prior to Day 21 (Day 19 and Day
20). If this is not the case, collection will stop as soon as
the recovered radioactivity is below 1% (per 24 h) for two
consecutive days after Day 21.
Total radioactivity analysis
TRA analysis was performed on a Liquid Scintillation
Counter Tri-Carp 2910 (PerkinElmer, Groningen,
The Netherlands). Aliquots of 200 μL of whole blood, plasma
and faeces (all in duplicate), and 1 mL of urine (in singular)
were transferred to scintillation vials. Whole blood and faecal
samples needed to be moderately translucent and colourless.
Therefore, 2-propanol (1 mL) was added to faecal samples to
dissolve fibres, NaEDTA (0.1 mL) was added to whole blood
to reduce foaming, and Solvable™ (1 mL) was added to both
matrices to solubilise tissue. Hydrogen peroxide 30% (0.4 mL
to faeces and 0.5 mL to whole blood) was added to reduce
colour intensity. These samples were placed in a water
bath (at least 40 °C; GF1086, Salm en Kipp, Breukelen,
The Netherlands) to stimulate the chemical processes.
Finally, 10 mL of Ultima Gold™ Cocktail (PerkinElmer)
was added and the samples were analysed, either for 60 min
or until the 2-sigma error was less than or equal to 5%,
whichever came first. A scintillant blank was used to
provide as a background sample. Results were expressed
as a percentage of the administered radioactive dose and
in niraparib equivalents for faeces and urine, and plasma
and whole blood respectively.
Quantification of niraparib and M1 in plasma and urine
Plasma and urine samples collected through 504 h after ad-
ministration were analysed using a validated bioanalytical
assay [11]. In brief, separation of niraparib and M1 was
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carried out using an HPLC Acquity I Class pump
(Waters, Milford, MA, USA) supplied with a SunFire C18
column (50 mm × 2.1 mm, 5 μm, Waters). Gradient
elution was applied using 20 mM ammonium acetate
in water (mobile phase A) and 0.1% formic acid in
acetonitrile-methanol (50:50, v/v; mobile phase B). The
validated calibration range of niraparib and M1 was 1–
500 ng/mL in plasma and 1–100 ng/mL in urine. Quality
control samples were prepared and analysed together with the
study samples. Sample analysis acceptance criteria for
bioanalytical data according to the FDA and EMA guidelines
[12, 13] were applied and results were reported using Analyst
5.2 software.
Pharmacokinetic analysis
Whole blood and plasma TRA data as well as niraparib
plasma concentrations were used to determine the maxi-
mum observed plasma concentration (Cmax), time to reach
maximum plasma concentration following drug ingestion
(tmax), the area under the plasma concentration-time curve
from time zero to time of last measurable concentration
(AUC0-last), and if the data allowed, area under the plasma
concentration-time curve from time zero to infinity
(AUC0-inf), apparent volume of distribution during termi-
nal phase Vd/F, apparent total clearance of the drug from
plasma after oral administration (CL/F), and the terminal
phase half-life (t1/2). Analysis was done by a non-
compartmental method using WinNonlin Phoenix
Version 6.2.1 or higher (Pharsight Corporation, St. Louis,
Missouri, USA).
Safety assessment
The safety of niraparib was evaluated during the study. The
National Cancer Institute Common Terminology Criteria for
Adverse Events (NCI CTCAE) grading system was used to
describe the severity of the adverse events (AEs) that oc-
curred. Haematology, blood chemistry and vital signs were
also part of the safety assessment.
Metabolite profiling
Sample selection
Metabolite profiling was divided into two parts: metabolite
screening and identification, and metabolite quantification.
During the first part, inter-patient pooled samples were
analysed to screen for the presence of metabolites.
Afterwards, individual patient samples or within-patient
pooled samples (depending on the matrix) were analysed
and metabolites found during the screening phase were quan-
tified. Plasma, urine and faeces samples were selected both for
screening and quantification. Three time points were selected
for screening of plasma samples. Besides the pre-dose, a sam-
ple around the tmax was chosen, because these samples
contained the highest amount of radioactivity. It was also of
interest to select a sample in which the amount of radioactivity
was much higher than the amount of parent compound, be-
cause this is indicative of the presence of metabolites.
Consequently, 4 h and 48 h were selected and screened for
metabolites. Individual patient samples from 0 h, 4 h, 12 h,
24 h, 48 h, 72 h and 168 h were analysed and metabolites in
these samples were quantified.
All urine samples were pooled within patients, and
afterwards these samples were pooled between patients.
For metabolite screening, the pre-dose, 0–24 h and 24–
72 h were pooled between patients and analysed. 24 h–
intervals were also pooled together within patients and
a pre-dose, 0–24 h, 24–72 h and 72–144 h were
analysed.
The same procedure was applied for faeces samples.
Again, 24 h-interval pools were made, first within patients
and then between patients. The latter were used for metabolite
screening, whereas the first were analysed afterwards, during
the quantification step. The time points that were chosen in-
cluded a pre-dose, 0–24 h, 24–72 h and 72–144 h, for both
screening and quantification.
Preparation of biological samples
Plasma Plasma samples (pre-dose, 4 h and 48 h) were pooled
by equal volumes. In addition, the individual samples (pre-
dose, 4 h, 12 h, 24 h, 48 h, 72 h and 168 h) were analysed.
Plasma samples were extracted once with acetonitrile-
methanol (50:50, v/v). The obtained supernatant was evapo-
rated to dryness and the dried supernatant was reconstituted in
10 μL 0.1% formic acid in acetonitrile and 90 μL 20 mM
ammonium acetate in water. An aliquot of the clear
supernatant was analysed for total radioactivity to deter-
mine extraction efficiency. The remaining supernatant
was used for analysis by LC-MSn in combination with
off-line LSC (LC-LSC-MSn).
Urine Urine samples were first pooled within patients. Three
pools (0–24 h, 24–72 h and 72–144 h) were prepared, after
which pools across patients were made. These samples were
analysed without pre-treatment.
Faeces Homogenised faeces samples were pooled, by equal
percentage of weight, across all subjects for selected time
periods (pre-dose, 0–24 h, 24–72 h and 72–144 h). Faeces
homogenate samples were extracted once with 0.1% formic
acid in acetonitrile. The obtained supernatant was evaporated
to dryness and the dried supernatant was reconstituted in
75 μL acetonitrile and 75 μL 20 mM ammonium acetate in
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water. An aliquot of the clear supernatant was analysed for
total radioactivity to determine extraction recovery. The re-
maining supernatant was used for LC-LSC-MSn analysis.
LC-MS/MS systems
Samples were analysed by LC (Shimadzu, Kyoto, Japan)
coupled to a linear ion trap mass spectrometer (Thermo
Electron, Waltham, MA, USA) in combination with off-line
LSC (LC-Linear Ion Trap LTQ XLMass Spectrometry (MS)-
LSC). To separate known and unknown metabolites, an
HPLC gradient was applied. A flow rate of 1 mL/min was
maintained during the following 50-min gradient: starting at
10%B and increasing to 36.25%B over 35 min, then to 90%B
in 12 min. This was held for 2 min and then it was reverted
back to the initial conditions of 10%B at 49min.Mobile phase
A consisted of 20mM ammonium acetate in water and mobile
phase B consisted of 0.1% formic acid in acetonitrile.
Structural information on niraparib metabolites was obtained
using Data Dependent Acquisition. Accurate mass measure-
ments were performed to confirm the chemical structures of
the metabolites. These measurements were performed on an
Ultimate 3000 LC (Dionex) coupled to an LTQ Orbitrap XL
MS (Thermo Electron, Waltham). The same gradient compo-
sition was applied. Additional LC-MS/MS settings can be
found in Tables 1 and 2.
Metabolite screening and identification
The metabolite profiles of 14C–niraparib-derived radioactivity
were determined for selected aliquots of extracts of
plasma, urine and faecal homogenates using LC-MS/
MS, fractionation and off-line LSC. After pre-treatment,
samples were injected onto a Phenomenex Synergi Hydro-RP
(250 × 4.6 mm, 4 μm) column. Data Dependent Acquisition
was applied, causing the detection and fragmentation of the
most abundant ions. Besides this, a parent list with possible
metabolites was constructed, meaning that apart from themost
abundant ions, also the ones with the masses in this parent list
were further fragmentised for which MS2 and MS3 spectra
were obtained. In between the HPLC and the MS a fraction
collector was placed, which collected 3/4th of the flow. The
remaining sample was analysed byMS. This fraction collector
was set at 1 fraction per minute, in other words 50 fractions
were collected per sample. LSC (Tri-Carb 4910 TR;
PerkinElmer, Waltham) was performed by adding Ultima
Gold™ scintillation cocktail to a sample followed by scintil-
lation counting for 20 min. The limit of detection (LOD) and
lower limit of quantification (LLOQ) were calculated based
on the formulas described in BCalculations^ section. The re-
sult from analysis by LSCwas a radiochromatogram, showing
radioactive fractions, which could be correlated directly with
the retention time of the peaks in the LC chromatogram.
Table 1 HPLC settings
Pump LC-20 AD (Shimadzu) Ultimate 3000 RSLC nanoSystem (Dionex)
Flow rate 1.0 mL/min 12 μL/min
Analytical column Phenomenex Synergi Hydro-RP (250 × 4.6 mm, 4 μm) Phenomenex Synergi Hydro-RP 80A (150 × 0.5 mm, 4 μ)
Column oven 35 °C Ultimate 3000 RSLC NanoSystem
Run time 50 min 60 min
Mobile phase A 20 mM ammonium acetate in H2O 20 mM ammonium acetate in H2O
Mobile phase B 0.1% HCOOH in ACN 0.1% HCOOH in ACN
Gradient composition Time (min) Mobile phase B (%) Time (min) Mobile phase B (%)
0.0 10 0.0 10
0.1 10 0.1 10
35.0 36.25 35.0 36.25
47.0 90 47.0 90
49.0 90 49.0 90
49.1 10 50.0 10




Autosampler SIL-HTc (Shimadzu) Ultimate 3000 RS autosampler (Dionex)
Tray temperature 4 °C 4 °C
Injection volume 0.050 mL (U + P); 0.010 mL (F) 1 μL
Splitter Accurate (LC packings) NA
Split ratio (collector:MS) 1:3 NA
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Metabolites were identified based on accurate masses of pro-
tonated molecular ions and their fragmentation patterns.
Authentic standards, when available, were used to compare
chromatographic retention times and fragmentation patterns.
Metabolite names were derived from Zhang et al. [9, 10],
except in the case of newly discovered metabolites. The
numbers designated in the radiochromatograms were
given in accordance with the retention time. Each me-
tabolite has therefore two names: a chronological num-
ber and an M-name (or a descriptive name in the case
of newly identified metabolites).
Metabolite quantification
Individual samples (in case of plasma) and individually
pooled samples (urine and faeces) were analysed in the same
manner as mentioned before. Here, metabolites identified dur-
ing screening were quantified and expressed as a percentage
of the administered dose, in the case of urine and faeces, and
as a percentage of the AUC0-168h from the total amount of
14C
administered in the case of plasma.
Calculations
For radioactivity analysis by LSC, the LOD and LLOQ were









LOD: Limit of detection (DPM)
T: Counting time (min)
E: Counting efficiency
B: Background radioactivity (DPM)
With a counting time of 20 min, an observed background of
11.0 disintegrations per minute (DPM) and a counting efficien-
cy of 93%, the LOD is 3.7 DPM, which is rounded to 4 DPM.
%2S ¼ 200
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ




%2 s: 2 times the standard deviation of the count
expressed as percentage of counts
CPMa: Total CPM of a sample
CPMb: CPM of the background
T: Counting time (min)
At the LLOQ the %2 s value should not exceed 20%. Thus,
with an observed background CPMb of 10.2, a %2 s value of
20 and a counting time of 20 min, the CPMa at the LLOQ is
23.2 CPM. With a counting efficiency of 93%, this corre-
sponds to a total LLOQ of 24.9 DPM. After subtraction of
the background the corrected activity at the LLOQ is 14 DPM.
Results
Patients
Six female patients, three with ovarian cancer, two with breast
cancer and one with colorectal cancer, were enrolled in the mass
balance study, with a median age of 55.5 (range 39–69), a mean
weight of 73.6 kg (range 64.3–92.3) and a mean height of
167.8 cm (range 159–176). Baseline characteristics can be found
in Table 3. All patients completed the first part of the study. Five
were eligible for the extension study and received daily treatment
with niraparib. All subjects enrolled in the extension study com-
pleted at least 2 cycles. Two patients have completed 7 or more
cycles at the cut-off date. All five patients received a dose reduc-
tion at some point due to the occurrence of an adverse event.
Table 2 MS settings
Mass spectrometer LTQ XL (Thermo Electron) LTQ Orbitrap discovery
(Thermo scientific)
Ionization/interface ESI, positive ionization mode ESI
Scan range 50–1100 80–1100
Valve 0–2 min (waste); 2–35 min (source);
35–50 min (waste)
Not used
Sheath gas flow 30 arb 15 arb
Aux gas flow 15 arb 0 arb
Sweep gas flow 5 arb 0 arb
Spray voltage 5 kV 5 kV
Normalised collision energy 35 V 32 V
Capillary Temperature 375 °C 270 °C
Capillary Voltage 40 V 46 V
Tube Lens 75 V 125
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Safety
At least one treatment-emergent adverse event (TEAE) was
reported for each patient enrolled in the study, with a total of
21 AEs reported. Gastrointestinal disorders occurred in four
patients and consisted of constipation, dyspepsia, dry mouth,
nausea, abdominal distension and ascites. Furthermore, der-
matitis acneiform occurred in two patients and fatigue, erysip-
elas, ASAT increase, myalgia, insomnia and pleuritic pain
were experienced by one patient. Six of these AEs were con-
sidered likely to be related to study treatment, including con-
stipation, dry mouth, nausea, dermatitis acneiform and ASAT
increase. All of these were grade 2 or lower and no TEAEs led
to study drug discontinuation or death.
Pharmacokinetics
A summary of pharmacokinetic parameters of 14C–radioactiv-
ity in plasma and whole blood, unlabelled niraparib, and
unlabelled major metabolite M1 in plasma is presented in
Table 4. Mean total 14C–radioactivity (expressed as
nanograms-equivalent per millilitre; ng.eq/mL) in whole blood
and plasma, and niraparib and M1 in plasma concentration-
versus-time data are shown in Fig. 2. Niraparib plasma
Table 3 Baseline characteristics
Characteristic Value
Age (Years)
Mean (StdDev) 55.5 (11.10)
Median 56.5






Not Hispanic Or Latino 6 (100)




Illicit Drug Abuse, N (%)
No 6 (100)
Chronic Alcohol Use, N (%)
No 6 (100)
Table 4 Summary of pharmacokinetic parameters of 14C radioactivity in plasma and whole blood, unlabelled-niraparib and unlabelled major
metabolite M1
Parameter Total 14C- radioactivity
plasma (n = 6)
Total 14C- radioactivity
whole blood (n = 6)
Unlabelled niraparib
plasma (n = 6)
Unlabelled M1
plasma (n = 6)
Cmax
a (ng/mL) Mean 3260 2110 540 476
CV% 42.4 48.3 30.5 39.4
tmax (h) Median 48.02 24.02 2.49 9.02
Range 23.98–48.40 3.00–72.03 1.52–5.98 5.98–24.20
AUC0-last
b (μg*h/mL) Mean 551 313 18.4 40.8
CV% 44.8 44.7 29.9 42.1
AUC0-inf
b (μg*h/mL) Mean 594 348 18.5 41.2
CV% 43.0 41.8 29.6 42.3
t1/2 (h) Mean 92.5 90.5 87.4 78.4
CV% 8.6 9.0 19.1 17.2
CL/F (L/h) Mean 0.601 1.01 17.2 NA
CV% 47.9 44.3 26.1 NA
Vd/F (L) Mean 79.7 130 2170 NA
CV% 49.1 41.2 32.2 NA
NA Not Applicable
AUC0-infArea under the plasma concentration-time curve from time 0 to infinity, AUC0-last Area under the plasma concentration-time curve
from time 0 to the last quantifiable concentration, CL/F Apparent oral clearance, Cmax maximum observed plasma concentration, CV
Coefficient of variation, NA Not applicable; tmax Time to reach maximum observed plasma concentration, t½ Terminal half-life, Vd/F
Apparent oral volume of distribution
a Cmax unit for
14 C–radioactivity is ng equivalent/mL
bUnit for AUCs for total 14 C–radioactivity is µg equivalent*hr./mL
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concentrations peaked at 2.49 h post-dose, with a mean max-
imum concentration of 540 ng/mL. Mean t½ for unlabelled
niraparib in plasma was 87.4 h, meaning that elimination of
niraparib took place slowly. Niraparib CL/F was approximate-
ly 17.2 L/h and the apparent Vd/F was 2170 L, indicating
niraparib distributes extensively into tissue.
Pharmacokinetic analysis for 14C–radioactivity in whole
blood and plasma showed that the amount of radioactivity in
plasma is 1.7 higher than in whole blood. This suggests that
niraparib metabolites are distributed more in plasma than in
red blood cells.
Mass balance
As shown in Fig. 3, over 50% of the administered dose was
already recovered within the first 4 days (96 h) after dosing. A
mean total of 86.3% of the administered radioactive dose was
recovered in excreta through 504 h post-dose, of which 47.5%
was recovered in urine and 38.8% was found in faeces. These
data demonstrate that both the hepatic/biliary route and renal
clearance are the predominant excretion routes for niraparib
and its metabolites. Collection of faeces and urine occurred in
accordance with the criteria mentioned in BSample collection^
section. This meant that collection was stopped after 21, 12,
10, 22, 17 and 11 days, for patients 1, 2, 3, 4, 5 and 6,
respectively.
Metabolites in plasma
Figure 4 shows the radiochromatograms for the plasma
screening samples. Peaks are numbered in chronological order
i.e. in order of retention time. Six compounds were detected in
the plasma matrix and quantified. Concentrations were
expressed in niraparib ng.eq/mL and ultimately AUC0-168h



























Fig. 2 Mean (±SD) log-linear
concentration-time profile of total
radioactivity (niraparib-related
compounds) in whole blood and
plasma after a single dose of
300 mg 14C–niraparib to patients
with advanced cancer (n = 6)









































Fig. 3 Mean (±SD) cumulative
recovered radioactivity in excreta
after a single dose of 300 mg 14C–
niraparib to patients with
advanced cancer (n = 6)
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values were calculated. These values were compared to the
total 14C–AUC0-168h and finally expressed as a percentage of
the 14C–AUC0-168h. The total radioactivity measured in the
fractions of these samples was low (up to 35 DPM). As ex-
pected, unchanged parent drug concentrations were lower in
the 48-h sample and higher concentrations ofmetabolites were
found as compared to the 4 h–sample. Niraparib (5) accounted
for only 2.4% of the relative 14C–AUC0-168h. M1 (4)
accounted for 9.3%, and unknown metabolites for the major-
ity (58.2%) of the radioactive dose. Of this, 55.7% was attrib-
uted to the M1 glucuronide (1), (2) and (3), and 2.5% was
accounted for by Methylated M1 (7). Finally, 1.1% of the
administered dose could not be accounted for in the radiochro-
matograms. A total of 69.9% of the total radioactivity was
explained and the remaining radioactivity was not recovered
due to sample pre-treatment loss, which was 29%.













































Fig. 4 Radiochromatogram of
plasma screening samples
collected 4 h (a) and 48 h (b) post-
dose. Note that the scale of the




Figure 5 shows the radiochromatograms from pooled urine
samples. The profile did not change considerably over time.
The predominant peaks found in urine were niraparib (5), M1
(4) andM10 (2), which accounted for 10.5, 20 and 6.2% of the
administered dose, respectively. A total of 36.7% of the
administered dose was explained by these compounds. Avery
small amount of the other glucuronidated forms of M1 (1) and
(3) as well as M9, monooxygenated dehydrogenated niraparib
(6), were detected, but were considered low abundant metab-
olites because of their low concentrations. A small portion of
3.3% of the administered dose was left unaccounted for and
could not be identified.













































Fig. 5 Radiochromatogram of
urine screening samples collected
0-24 h (a) and 24-72 h (b) post-
dose. Note that the scale of the
y-axis is different in each
radiochromatogram.
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Fig. 6 Radiochromatogram of
faeces screening samples
collected 0-24 h (a), 24-72 h (b)
and 72-144 h (c) post-dose. Note





Figure 6 shows the radiochromatograms from pooled faeces
samples. The profile was very similar in both selected sam-
ples, with only two compounds detected. The majority was
assigned to niraparib (5), accounting for 18.7% of the admin-
istered dose, whereas only 2.4% was excreted via faeces as
M1 (4). A small fraction of 1.2% of the radioactivity could not
be accounted for in the radiochromatograms and 9.3% was
lost during sample pre-treatment.
Metabolite identification
The structural characterisation and identification of all metab-
olites is described below. An overview of all metabolite char-
acteristics can be found in Table 5.
Niraparib (5)
The identity of niraparib was confirmed by comparing the
obtained mass spectra and retention timewith the mass spectra
and retention time of the reference standard. The MS2 spectra
showed a product ion of m/z 304, which corresponds to the
loss of NH3. The MS
3 spectra also showed m/z 276, which
indicates an additional loss of 28, and can be attributed to the
loss of CO.
M1 (4)
M1 was identified similarly to niraparib. Reference standards
were available andMS/MS2/MS3 spectra from these reference
standards and observed peaks in the chromatogram showed
strong similarities. Moreover, the retention times were identi-
cal. The MS2 spectra showed a product ion of m/z 304, which
corresponds to the loss of H2O. TheMS
3 spectra is identical to
the niraparib spectra. It is therefore confirmed that niraparib
and M1 have identical fragmentation patterns.
M10 (1), (2) and (3)
The MS spectra of metabolites (1), (2) and (3) are similar and
show a parent protonated mass ofm/z 498. In the MS2 spectra
two ions were detected:m/z 322, the mass ofM1 (4), (after the
loss of 176 Da, indicating the presence of a glucuronide
group) and m/z 304 (an additional loss of H2O). The MS
3
spectra of metabolites (1), (2) and (3) show similar ions as
detected for M1 (4). These data support the identification of
M1 glucuronides (M10). Compounds (1) and (3) showed ad-
ditional product ion m/z 480 in the MS2 spectra. The loss of
18 Da could indicate a loss of H2O. This could suggest N-
glucuronides rather than O-glucuronides. However, the posi-
tion of the glucuronide group could not be confirmed solely


























































































































































































































































































































































































































































































































































































































































































































































Compound (7) shows a parent ion of m/z 336. MS2 and MS3
spectra show similar patterns as niraparib (5),M1 (4) andM10
(1) and (3), with product ion m/z 304 and a fragmentation
pattern with m/z 263, 235 and 276. It was, based on the high
resolution mass data, confirmed as a methylated M1. Even
though methylations belong to the less common phase II bio-
transformations, these types of reactions have found to occur
especially for substrates that contain -C, −N, −O and -S func-
tional groups [14]. This results, in contrast to most other phase
II conjugation reactions, in more hydrophobic metabolites.
This conclusion is supported by the fact that this compound
elutes later than all other metabolites, which can be explained
by the reduction of hydrophilicity by binding to the O-
functional group, thus making the compound less polar [15].
M9 (6)
Compound (6) shows a protonated ion atm/z 336. The product
ion ofm/z 318 likely results from a loss of H2O. The additional
loss of CO produces a fragment of m/z 290. This again can be
fragmentised to eventually a product with m/z 231, due to
subsequent losses of NH3, CH3N, CH3NO and C2H5NO.
Discussion
This was a mass balance study conducted in six female volun-
teers with various types of cancer at a single study center, and it
investigated the absorption, metabolism and excretion of 14C–
niraparib after a single oral dose of 300 mg. The niraparib Cmax
concentration of 540 ng/mL was observed at 2.49 h post-dose
(tmax). Niraparib was eliminated biphasically with a mean t1/2 of
87.4 h. The t1/2 for total radioactivity in plasma was slightly
longer, which is explained by the longer t1/2 of niraparib me-
tabolites. A plasma-concentration time curve of niraparib and
metabolites can be found in Fig. 7. The apparent clearance was
approximately 17.2 L/h. The plasma:whole blood ratio of 1.7,
based on AUC0-inf of the total radioactivity illustrates that me-
tabolites distribute more in plasma than in red blood cells. This
is consistent with red blood cell partitioning experiments done
previously (data unpublished). It is important to note that it is
the metabolites that distribute more into red blood cells, while

































Fig. 7 Mean log-linear
concentration-time profiles of
radioactive metabolites found in





























Fig. 8 Summary of niraparib
metabolite excretion through
144 h after a single oral dose of
14C-niraparib
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niraparib penetrates more into tissues. This finding could be an
important differentiation factor for niraparib efficacy.
The apparent Vd/F of niraparib in humans, while consis-
tently high, has shown variations across the clinical studies.
For example, in the patients in Part 1of this AME study des-
ignated for the determination of absolute oral bioavailability,
the apparent Vd/F was determined to be 1220 L (data not
shown). Moreover, based on the population pharmacokinetic
analysis on all the patients in NOVA study [3], the apparent
Vd/F was 1074 L. Collectively, it would be conceivable to
conclude that the apparent Vd/F for niraparib appears to be
quite high, at least 1000 L in cancer patients.
The main elimination routes of niraparib and its metabolites
are both the hepatic/biliary and the renal routes. Mean total ra-
dioactivity recovered in urine and faeces was 86.3% (71.1 -
91.0%) of the total administered dose, of which 47.5% (33.4 -
60.2%) was recovered in urine and 38.8% (28.3% - 47.0%) in
faeces through 504 h post-dose. Metabolite profiling was done
for plasma samples up to 168 h and for urine and faeces samples
up to 144 h. Up to 144 h, a total of 71.6% of the administered
dose was recovered in excreta, 40 and 31.6% in urine and faeces,
respectively. A summary can be found in Fig. 8.
The metabolite profiles obtained by LC-LSC-MSn analysis
revealed that unchanged niraparib (5) was the predominant
radioactive component in faeces, whereas M1 (4) was the
main radioactive metabolite in urine. The glucuronidated form
of M1, M10 (1), (2) and (3) was the main circulating metab-
olite in plasma and was considered the only major metabolite
in addition to M1. Minor metabolites included M9 (6) and
Methylated M1 (7). The chemical structures of these metabo-
lites were confirmed by high resolution techniques, with mass
spectra accuracy within 5 ppm. From these data it can be
concluded that niraparib undergoes hydrolysis and conjuga-
tion, with the oxidative pathway seen in vitro being minimal
[9]. A proposed metabolic pathway can be found in Fig. 9.
M10 (1), (2) and (3) was largely present in plasma and was
only eliminated via the urine. The minor metabolites M9 (6)
and methylated M1 (7) were also detected, of which the latter
was quantified in plasma and not detected in urine. M9 was
not detected in plasma, but was quantified in urine, albeit it
being a low abundant metabolite. Metabolite M10 was a ma-
jor metabolite and was found in three forms (1), (2) and (3).
Based onMS data, it cannot be concluded what the position of
the glucuronide on M1 is, although it could be suggested that
in the case of (1) and (3), N-glucuronides are more likely, due
to the detection of m/z 480 in the MS2 spectrum.
Upon comparing the metabolism data reported here with the
data obtained from in vivo and in vitro studies [9, 10] it be-
comes apparent that not all metabolites detected in the animal
studies have been detected in human plasma and/or excreta. For
instance, the glucuronide of niraparib (M20), was not detected
during the metabolite profiling of this study, nor were M2
(mono-oxygenated niraparib) and M8 (carbonyl of niraparib),
whereas they were identified in human hepatocytes.
It has been demonstrated that both carboxylesterases (CEs)
and CYP enzymes play a role in Phase 1 metabolism of
niraparib in vitro. However, CE-mediated amide hydrolysis
of niraparib to formM1 has been evidently shown as virtually
Fig. 9 Proposed metabolic
pathway of niraparib in humans
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the only primary pathway in cancer patients in this study,
suggesting the minimal role of CYPs in niraparib metabolism.
An adequate amount of faecal and plasma samples was lost
during sample clean-up, which was demonstrated by loss of
radioactivity in each analysed sample. Therefore, it is impos-
sible to rule out the potential losses of (minor) metabolites.
When a trend is seen over time, the conclusion could be that
the losses are compound-specific. For instance, if the amount
of radioactivity lost increases with time (i.e. with increasing
concentration of an analyte), and then decreases again (with
decreasing concentration of that analyte), this could be indica-
tive of losses of this one specific analyte. Such a trend was not
observed and therefore it cannot be concluded that these losses
were compound-specific. Nevertheless, no conclusions can be
drawn about whether the compounds in the sample were lost to
the same extent. Efforts were made to improve extraction re-
covery, but were hampered by the limited amount of plasma
samples available. After achieving 70% extraction recovery, it
was decided to stop the developmental phase in order to ensure
that sufficient amounts were left for the experimental phase.
Faeces sample pre-treatment improved by changing extraction
solvents and by dissolving dried extracts into the organic phase
before adding the aqueous phase. This increased extraction
efficiency from approximately 20 to 90%.
In conclusion, it was shown that niraparib is moderately
metabolised in humans via hydrolytic and conjugative path-
ways. 31.6% of the total administered dose was recovered in
faeces and 40.0% was excreted in urine 144 h post-dose.
Unchanged niraparib accounted for 29.9% of the dose excret-
ed in urine and faeces. Furthermore, M1 (2.4%) was detected
in faecal samples, and M1 (20.0%) and M10 (6.2%) were
quantified in urine. The high volume of distribution and long
elimination half-life seen in this study may be consistent with
the anti-cancer activity of niraparib.
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